Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emapalumab for CAR T-Cell Therapy-Associated Prolonged Cytopenia
NCT06285825Phase 2Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Jul 2024
- Primary completion
- Aug 2028
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of emapalumab in cytopenia, sponsored by University of Texas MD Anderson Cancer Center. Started Jul 2024; status: recruiting.
02
Drugs
emapalumab
03
Conditions
cytopenia
Beyond the preview
Go deeper on NCT06285825.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06285825.